Role of vascular endothelial growth factor D in lung adenocarcinoma immunotherapy response
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Vascular Endothelial Growth Factor D (VEGFD) is linked to innate immunity and predicts lung adenocarcinoma (LUAD) prognosis. VEGFD may also predict response to anti-PD-1 immunotherapy in LUAD patients.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Tumor-associated macrophages (TAMs) play a crucial role in tumor progression and immune evasion.
- Understanding the genetic landscape associated with TAMs is vital for developing effective lung adenocarcinoma (LUAD) therapies.
- Identifying biomarkers for immunotherapy response can improve patient outcomes.
Purpose Of The Study
- To identify key genes associated with TAMs and tumor immunotherapy in LUAD prognosis.
- To construct a prognostic risk model for LUAD based on TAM-associated genes.
- To validate the predictive role of identified genes in immunotherapy response.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) database for LUAD mRNA expression profiles.
- Employed CIBERSORT to analyze immune cell infiltration and WGCNA, LASSO, and Cox regression for risk model construction.
- Validated findings in the IMvigor210 cohort and used tissue microarrays and immunofluorescence staining.
Main Results
- Identified significant differences in innate immune cells between LUAD and normal tissues.
- Discovered four hub genes, including Vascular Endothelial Growth Factor D (VEGFD), as independent prognostic risk factors.
- VEGFD was a low-risk factor, associated with better LUAD prognosis and higher sensitivity to anti-PD-L1 therapy.
Conclusions
- VEGFD is significantly associated with innate immunity in LUAD.
- VEGFD can serve as a predictive biomarker for LUAD prognosis.
- VEGFD shows potential as a predictor for anti-PD-1 treatment efficacy in LUAD patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...